Cas:104010-72-2 (3aS,6aS)-2,2-dimethyl-3a,6a-dihydrocyclopenta[d][1,3]dioxol-4-one manufacturer & supplier

Chemical Name:(3aS,6aS)-2,2-dimethyl-3a,6a-dihydrocyclopenta[d][1,3]dioxol-4-one

CAS.NO:104010-72-2

Synonyms:(+)-(3aS,6aS)-3a,6a-Dihydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-one;qc-361;(3aS,6aS)-2,2-Dimethyl-3a,6a-dihydro-4H-cyclopenta[d][1,3]dioxol-4-one;4H-Cyclopenta[d]-1,3-dioxol-4-one, 3a,6a-dihydro-2,2-dimethyl-, (3aS,6aS)-

Molecular Formula:C₈H₁₀O₃

Molecular Weight:154.163

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:243.8±40.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.482

PSA:35.53000

Exact Mass:154.062988

LogP:0.15

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (+)-(3aS,6aS)-3a,6a-Dihydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4H-Cyclopenta[d]-1,3-dioxol-4-one, 3a,6a-dihydro-2,2-dimethyl-, (3aS,6aS)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(3aS,6aS)-2,2-Dimethyl-3a,6a-dihydro-4H-cyclopenta[d][1,3]dioxol-4-one Use and application,4H-Cyclopenta[d]-1,3-dioxol-4-one, 3a,6a-dihydro-2,2-dimethyl-, (3aS,6aS)- technical grade,usp/ep/jp grade.

Related News: Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm. (3aS,6aS)-2,2-dimethyl-3a,6a-dihydrocyclopenta[d][1,3]dioxol-4-one manufacturer Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more. (3aS,6aS)-2,2-dimethyl-3a,6a-dihydrocyclopenta[d][1,3]dioxol-4-one supplier This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. (3aS,6aS)-2,2-dimethyl-3a,6a-dihydrocyclopenta[d][1,3]dioxol-4-one vendor It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing. (3aS,6aS)-2,2-dimethyl-3a,6a-dihydrocyclopenta[d][1,3]dioxol-4-one factory It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.